LivingGLP1
crossover randomized trial

S002961

Design

Randomized
37
Start year
Treatment
Countries
China (1 sites)
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical (industry)
Eligibility
healthy Chinese adults 18 to 45, weight 50 kg or more, BMI 19 to 26

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1liraglutide
Test liraglutide 0.6 mg single dose
lifestyle: not reported3736
A2liraglutide
Victoza 0.6 mg single dose
lifestyle: not reported3736

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticTest liraglutide 0.6 mg single dose
A1
Victoza 0.6 mg single dose
A2
Whole trial
ALL
agemax (years)41
agemean (years)27.3
agemin (years)18
agesd (years)6.47
bmimean (kg/m2)22.53
bmisd (kg/m2)1.677
femalen14
femalepercent38.9
other ethnicity hann34
other ethnicity hanpercent94.4
other ethnicity other nationalitiesn2
other ethnicity other nationalitiespercent5.6
weightmean (kg)62.04
weightsd (kg)6.890

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (2 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 36not stated; safety; R0009787:Table 2
A2events0 / 36not stated; safety; R0009787:Table 2
Discontinuation due to adverse events (2 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 36not stated; safety; R0009787:Table 2
A2events0 / 36not stated; safety; R0009787:Table 2
Discontinuation due to gastrointestinal adverse events (2 lines; O27E)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 36not stated; safety; R0009787:Table 2
A2events0 / 36not stated; safety; R0009787:Table 2